Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

NCT ID: NCT02954172

Last Updated: 2020-12-08

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 450 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-11-28
• Study Completion Date: 2019-11-12

Brief Summary

A randomized, double blind, multicenter phase3 study .

Detailed Description

A randomized, double blind, multicenter phase3 study in chemotherapy naive patients with stage IIIB,IV or recurrent NSCLC of non-squamous. the study will randomize about 436 patients at a 1:1 ratio to 2 treatment arms. The study is divided 4 phase, screening, combination treatment, maintenance and follow up.

Conditions

NSCLC

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Bevacizumab in Combination With Paclitaxel/Carboplatin

Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Group Type: EXPERIMENTAL

Bevacizumab in Combination With Paclitaxel/Carboplatin

Intervention Type: DRUG

Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

IBI305 in Combination with Paclitaxel/Carboplatin

Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Group Type: ACTIVE_COMPARATOR

IBI305 in Combination with Paclitaxel/Carboplatin

Intervention Type: DRUG

Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Interventions

Bevacizumab in Combination With Paclitaxel/Carboplatin

Drug Bevacizumab15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Intervention Type: DRUG

IBI305 in Combination with Paclitaxel/Carboplatin

Drug IBI305 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg

Intervention Type: DRUG

Other Intervention Names

Avastin; Bevacizumab Biosimilar

Eligibility Criteria

Inclusion Criteria

1. signed inform consent form(ICF)

2. Age ≥ 18 years and ≤ 75 years, male or female

3. Histologically or cytologically documented inoperable, local advanced (stage IIIB), metastatic (stage IV), or recurrent non-squamous NSCLC; Mixed tumors should be categorized according to the predominant cell type

4. Histologically confirmed epidermal growth factor receptor (EGFR) wild type or insensitive mutation

5. At least one measurable lesion according to Response Evaluation Criteria In Solid Tumors（RECISIT） v 1.1

6. Eastern Cooperative Oncology Group(ECOG) performance status of 0 or 1

7. Life expectancy ≥ 6 months

8. Laboratory results:

1. Adequate hematologic function, defined as absolute neutrophil count ≥1.5×10^9 /L, platelet count ≥100 ×10^9 /L, hemoglobin ≥90g/L;

2. Adequate liver function, defined as total bilirubin levels ≤ 1.5 times normal upper limit (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ≤ 2.5 times ULN, or AST and ALT levels ≤ 5 times ULN for patients with hepatic metastasis;

3. Adequate renal function, defined as serum creatinine ≤ 1.5 times ULN or creatinine clearance ≥ 50 ml / min (Cockcroft-Gault formula) and proteinuria < 2+;

4. Coagulation function is adequate, defined as international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 times normal upper limit (ULN), PTT or aPTT ≤ 1.5 times ULN;

9. Expected protocol compliance

10. Patients of childbearing potential must agree to use effective contraceptive measures during study treatment and for 6 months after receiving last study treatment (e.g. abstinence, sterilization surgery, oral contraceptives, contraception by progesterone injection or subcutaneous).

Exclusion Criteria

1. Prior chemotherapy or target therapy with another systemic anti-cancer agent (e.g., monoclonal antibody, tyrosine kinase inhibitor) for the treatment of the patient's current stage of disease (Stage IIIB not amenable for combined modality treatment, stage IV or recurrent disease). Prior surgery and irradiation is permitted, provided that the criteria outlined in the protocol for both treatments are met. Disease progressed within 6 months after adjuvant therapy must be excluded.

2. Mixed non-small cell and small cell carcinoma, or mixed adenosquamous carcinomas with predominant squamous cell

3. Histologically or cytologically confirmed EGFR sensitive mutation type, unknown EGFR status for any reason is allowed in this study.

4. Known hemoptysis within 3 months prior to screening with blood volume more than 2.5 mL each time

5. Evidence of tumor invading major blood vessels on imaging. The investigator or the local radiologist must exclude evidence of tumor that is fully contiguous with, surrounding, or extending into the lumen of a major blood vessel (e.g., pulmonary artery or superior vena cava)

6. Evidence of brain metastasis, spinal cord compression or carcinomatous meningitis history with clinical symptoms. For stable patients with no symptom, could be admitted if fulfill all below criteria: measurable lesion(s) out of CNS, no metastasis at mesocephalon, annular protuberance, medulla oblongata and spinal cord; no history of intracranial bleeding.

7. Radical radiotherapy to the thorax with curative intent within 28 days prior to enrollment; palliative radiotherapy for bone lesions outside the thoracic region within 2 weeks prior to first dose of study treatment.

8. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major surgical procedure within 28 days prior to randomization or anticipation of need for major surgery during the course of the study.

9. Minor surgery (Including insertion of an indwelling catheter) within 48 hours prior to first dose of study treatment

10. Recent or current (within 10 days prior to first dose of study treatment) receive treatment of Aspirin (> 325 mg/day) or other non-steroidal anti-inflammatory drugs (NSAID) known to inhibit platelet function (within 10 days prior to first dose of study treatment)

11. Recent or current receive treatment of oral all doses of oral or parenteral anticoagulants or thrombolytic agent. Prophylactic use of anticoagulants is permitted.

12. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus

13. Uncontrolled hypertension (SBP>140 mmHg and/or diastolic blood pressure>90 mmHg), prior history of hypertensive crisis and hypertensive encephalopathy

14. Clinically significant cardiovascular disease but not limited to active infections; unstable angina; stroke or transient cerebral ischemia (within 6 months prior to screening); myocardial infarction (within 6 months prior to screening) ; congestive heart-failure (New York Heart Association (NYHA) class≥ II) ; serious cardiac arrhythmia, hepatic, renal or metabolic disease requiring medication during the study.

15. History of peptic ulcer, gastrointestinal perforation, erosive esophagitis, erosive gastritis, inflammatory bowel disease or diverticulitis, abdominal fistula or intra-abdominal abscess within 6 months prior to screening

16. Patient diagnosed with a tracheo-esophageal fistula

17. Clinically significant third space effusion (e.g., uncontrolled ascites or pleural effusion by extraction or other treatment)

18. Pulmonary fibrosis or active pneumonia showed by CT at baseline

19. Active malignancy other than non-small cell lung cancer (NSCLC), treated carcinoma in situ of the cervix, superficial basal cell or squamous cell carcinoma, radical surgery of localized prostate cancer, radical surgery of ductal carcinoma in situ within 5 years prior to randomization

20. Known autoimmune disease

21. Known positive HbsAg and hepatitis B virus (HBV)-DNA drop test in peripheral blood ≥ 1 x 10^3 copy number/L or 200 IU/mL; If HBsAg positive and HBV-DNA drop test in peripheral blood < 1 x 10^3 copy number/L or 200 IU/mL, patient is considered to be eligible by investigator only when chronic hepatitis B in the plateau and do not increase the risk

22. Known positive HIV or hepatitis C virus (HCV) or syphilis

23. Known allergic disease or allergic physique

24. Treatment with any other investigational agent or participation in another clinical trial within 30 days prior to screening

25. Known alcoholism or drug abuse

26. Pregnant or anticipation of pregnant during the study or lactating women

27. Known hypersensitivity to bevacizumab or any of its excipients and/or any of the chemotherapy agents

28. Other conditions that the investigator thinks unsuitable in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

WuXi CDS Clinical Research (Shanghai) Co.Ltd.

INDUSTRY

Sponsor Role: collaborator

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Li Zhang, Doctor

Role: PRINCIPAL_INVESTIGATOR

Sun Yat-sen University

Locations

Cancer Center; Sun Yat sen University;

Guangzhou, Guangdong, China

Countries

China

References

Yang Y, Wu B, Huang L, Shi M, Liu Y, Zhao Y, Wang L, Lu S, Chen G, Li B, Xie C, Fang J, Yang N, Zhang Y, Cui J, Song Y, Zhang C, Mei X, Cao B, Yang L, Cheng Y, Ying K, Sun T, Ren B, Yu Q, Liao Z, Pei Z, Wang M, Zhou J, Yu S, Feng G, Wan H, Wang H, Gao S, Wang J, An G, Geng Y, Ji Y, Yuan Y, Ma S, Jia Z, Hu M, Zhou H, Yu J, Sun X, Zhang L. Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer. Transl Lung Cancer Res. 2019 Dec;8(6):989-999. doi: 10.21037/tlcr.2019.12.23.

Reference Type: DERIVED

PMID: 32010577 (View on PubMed)

Provided Documents

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

CIBI305A301

Identifier Type: -

Identifier Source: org_study_id